What were the underlying drivers of the increase in clinical test volume (e.g., new contracts, pricing changes, new product adoption)?
Key driver identified in the release
The PersonalisâŻQ2â2025 earnings announcement points to a single, explicit catalyst for the jump in test volume:
- Accelerating physician adoption of the NeXTâŻPersonalÂź test â The company notes that the 3,478 clinical tests performed in the quarter (a 59âŻ% sequential rise over Q1âŻ2025) âdemonstrates accelerating physician adoption of the NeXTâŻPersonalÂź.â This test is the cornerstone of Personalisâ âWinâinâMRDâ strategy and is the primary reason the company cites for the higher volume.
What that likely means in practice
While the press release does not spell out every underlying factor, the language around âclinical adoption accelerationâ and the âWinâinâMRDâ strategy suggests a few concrete levers that typically drive such growth in a genomicsâtesting business:
| Potential underlying levers | How they tie to the reported increase |
|---|---|
| New or expanded contracts with healthâsystem partners â The âWinâinâMRDâ approach often involves formal agreements (e.g., bundledâtest agreements, payer contracts, or multiâsite rollâouts) that give physicians a readyâtoâorder pathway to the NeXTâŻPersonalÂź assay. | |
| Product rollout and broader availability â The NeXTâŻPersonalÂź test is a relatively new offering. As it moves from earlyâadopter sites to a wider network of oncologists and pathology labs, the number of orders naturally climbs. | |
| Pricing or reimbursement alignment â A genomics company will frequently adjust pricing structures or secure favorable reimbursement codes to make a test more attractive to providers. Although the release does not mention a price change, the âaccelerating physician adoptionâ phrasing is consistent with a marketâready pricing model that reduces barriers to ordering. | |
| Clinicalâevidence and guideline endorsements â The âWinâinâMRDâ strategy is built around demonstrating the testâs clinical utility (e.g., detecting residual disease earlier). New data, conference presentations, or guideline citations can prompt physicians to order the assay more readily. | |
| Marketing and education initiatives â Targeted outreach, webinars, and decisionâsupport tools that educate oncologists about the NeXTâŻPersonalÂź workflow can translate into higher test volumes. |
Bottom line
Based on the information disclosed in the BusinessâŻWire release, the primary and explicitly stated driver of the 59âŻ% sequential increase in clinical test volume is the rapidly growing physician adoption of Personalisâ NeXTâŻPersonalÂź test, which is a central component of the companyâs âWinâinâMRDâ strategy. The phrasing âclinical adoption accelerationâ implies that this adoption is being fueled by a combination of:
- New or expanded service contracts with healthâsystem partners,
- Wider product rollout and availability of the NeXTâŻPersonalÂź assay,
- Potential pricing or reimbursement alignment that eases ordering,
- Strengthening clinical evidence and guideline support, and
- Focused marketing/education efforts.
These elements together create a momentum loopâmore physicians order the test, more data are generated to support its utility, and the testâs market presence expandsâresulting in the pronounced volume uplift reported for Q2âŻ2025.